trending Market Intelligence /marketintelligence/en/news-insights/trending/qaRU5gbNWG1UItQozZBBBQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Roche's MabThera gets European Commission nod for rare autoimmune disease

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Roche's MabThera gets European Commission nod for rare autoimmune disease

Roche Holding AG said the European Commission approved MabThera for patients with pemphigus vulgaris, a rare condition affecting the skin and mucus membranes.

Pemphigus vulgaris is characterized by progressive painful blistering that can lead to life-threatening fluid loss, infection or death. The EU regulator approved MabThera, or rituximab, for patients with moderate to severe types of the disease.

The approval is based on data from a phase 3 study, called Ritux 3, which compared a combination of MabThera plus short-term corticosteroids to corticosteroids alone as an initial treatment for patients with newly diagnosed moderate to severe disease. In the study, 89.5% of those treated with the MabThera combination went into remission, compared with 27.8% of those who took steroids alone.

MabThera is a monoclonal antibody that targets the B-lymphocyte antigen CD20, which is mainly found on the surface of immune cells.

MabThera, also sold in the U.S. as Rituxan, was approved by the U.S. Food and Drug Administration in June 2018 for treating pemphigus vulgaris. The U.S. FDA first approved rituximab in 1997 to treat patients with a certain type of non-Hodgkin lymphoma.

Basel, Switzerland-based Roche is facing biosimilar competition for MabThera in the EU, primarily from Novartis AG's Rixathon.